NUP98-MLL fusion in human acute myeloblastic leukemia

Blood

Volumn 116, Issue 13, 2010, Pages 2332-2335

  Kaltenbach, Sophie ^a   Soler, Gwendoline ^b,c   Barin, Carole ^d   Gervais, Carine ^e   Bernard, Olivier A ^a,f   Penard Lacronique, Virginie ^a,f   Romana, Serge P ^b,c  

^a INSERM   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d UNIVERSITY HOSPITAL OF TOURS   (France)

^e UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^f Batiment 121   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE H3; HYBRID PROTEIN; LYSINE; LYSINE 79; LYSINE DERIVATIVE; METHIONINE; MIXED LINEAGE LEUKEMIA PROTEIN; NUCLEOPORIN 98; UNCLASSIFIED DRUG;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ARTICLE; CASE REPORT; CELL TRANSFORMATION; CHROMOSOME 11P; CHROMOSOME 11Q; CHROMOSOME ABERRATION; CHROMOSOME INVERSION; FEMALE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HOMEOBOX; HUMAN; MALE; PRIORITY JOURNAL;

EID: 77957717510     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-04-277806     Document Type: Article

References (19)

1. Soshnikova N, Duboule D. Epigenetic regulation of vertebrate Hox genes: a dynamic equilibrium. Epigenetics. 2009;4(8):537-540.
2. Liedtke M, Cleary ML. Therapeutic targeting of MLL. Blood. 2009;113(24):6061-6068.
3. Slany RK. The molecular biology of mixed lineage leukemia. Haematologica. 2009;94(7):984-993.
4. Andreeff M, Ruvolo V, Gadgil S, et al. HOX expression patterns identify a common signature for favorable AML. Leukemia. 2008;22(11):2041-2047.
5. Jin S, Zhao H, Yi Y, Nakata Y, Kalota A, Gewirtz AM. c-Myb binds MLL through menin in human leukemia cells and is an important driver of MLL-associated leukemogenesis. J Clin Invest. 2010;120(2):593-606.
6. Yokoyama A, Somervaille TC, Smith KS, Rozenblatt-Rosen O, Meyerson M, Cleary ML. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell. 2005;123(2):207-218. (Pubitemid 41457212)
7. Caslini C, Yang Z, El-Osta M, Milne TA, Slany RK, Hess JL. Interaction of MLL amino terminal sequences with menin is required for transformation. Cancer Res. 2007;67(15):7275-7283. (Pubitemid 47206556)
8. Nakamura T. NUP98 fusion in human leukemia: dysregulation of the nuclear pore and homeodomain proteins. Int J Hematol. 2005;82(1):21-27. (Pubitemid 41512194)
9. Romana SP, Radford-Weiss I, Ben Abdelali R, et al. NUP98 rearrangements in hematopoietic malignancies: a study of the Groupe Francophone de Cytogénétique Hématologique. Leukemia. 2006;20(4):696-706.
10. Oka M, Asally M, Yasuda Y, Ogawa Y, Tachibana T, Yoneda Y. The mobile FG nucleoporin Nup98 is a cofactor for Crm1-dependent protein export. Mol Biol Cell. 2010;21(11):1885-1896.
11. Capelson M, Liang Y, Schulte R, Mair W, Wagner U, Hetzer MW. Chromatin-bound nuclear pore components regulate gene expression in higher eukaryotes. Cell. 2010;140(3):372-383.
12. Kalverda B, Pickersgill H, Shloma VV, Fornerod M. Nucleoporins directly stimulate expression of developmental and cell-cycle genes inside the nucleoplasm. Cell. 2010;140(3):360-371.
13. Lam DH, Aplan PD. NUP98 gene fusions in hematologic malignancies. Leukemia. 2001;15(11):1689-1695.
14. Takeda A, Sarma NJ, Abdul-Nabi AM, Yaseen NR. Inhibition of CRM1-mediated nuclear export of transcription factors by leukemogenic NUP98 fusion protein. J Biol Chem. 2010;285(21):16248-16257.
15. Xu S, Powers MA. Nup98-homeodomain fusions interact with endogenous Nup98 during interphase and localize to kinetochores and chromosome arms during mitosis. Mol Biol Cell. 2010;21(9):1585-1596.
16. Wang GG, Song J, Wang Z, et al. Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD finger. Nature. 2009;459(7248):847-851.
17. Beillard E, Pallisgaard N, van der Velden VH, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using "real-time" quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR): a Europe against cancer program. Leukemia. 2003;17(12):2474-2486.
18. Dorrance AM, Liu S, Yuan W, et al. Mll partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alterations. J Clin Invest. 2006;116(10):2707-2716.
19. Bursen A, Schwabe K, Ruster B, et al. The AF4.MLL fusion protein is capable of inducing ALL in mice without requirement of MLL.AF4. Blood. 2010;115(17):3570-3579.